



## ICON Releases Latest Version of its Digital Platform, Providing Integrated Patient Services and Harmonised Data in One Platform

June 26, 2023

*Latest features support greater patient centricity and speed in study start-up*

DUBLIN--(BUSINESS WIRE)--Jun. 26, 2023-- [ICON plc](#), (NASDAQ: ICLR) a world-leading healthcare intelligence and clinical research organisation, today announced the latest release of its [Digital Platform](#). The platform supports seamless integration of ICON patient, site and sponsor services with the delivery of harmonised data and can be customised for any study design, from traditional to fully decentralised, and for any therapeutic area.

The ICON Digital Platform is an end-to-end solution that enables patient services throughout clinical trials including an easy-to-use patient mobile app, eConsent, eCOA, direct data capture for in-home services, televisits and digital health technology management. It offers the technical functionality, standard capability and integrated services, in one platform, that enable flexibility for any clinical trial.

Features of the ICON Digital Platform include the eCOA module which is pre-loaded with the validated [Mapi Research Trust](#) library, instruments and translations, reducing eCOA set-up during study start-up. It also supports the seamless integration of the [FIRECREST Site Portal](#) for training and communications, [Clinical Trial Tokenisation](#), digital outreach for patient recruitment and laboratory data, along with reporting dashboards and analytics.

Connecting and engaging patients in decentralised clinical trials is of increasing importance and ICON offers a wide range of customised, clinical and technical [Concierge Services](#) to support users of the Digital Platform including enrolment and on-boarding, technology and device logistics support, adherence check-ins and study completion services.

The platform deployment and management are governed by ICON's robust regulatory framework, and this, along with its global scalability capabilities, including language localisation, reduces regulatory compliance risk for sponsors.

Steve Cutler, CEO, ICON, commented: *"This newest version of the Digital Platform enables the efficient capture and delivery of quality data from a range of decentralised clinical trial services. Its ease of use enables greater patient centricity, reducing the barriers to trial participation and enhancing the equity, diversity and inclusion of patient populations."*

Built on a scalable cloud-first framework, API first architecture, this modular and fully configurable platform reduces deployment and study start-up timelines and enables interoperability of key operational systems.

For further information the ICON Digital Platform please visit [www.iconplc.com/digital-platform](http://www.iconplc.com/digital-platform).

### Ends

This press release contains forward-looking statements, including statements about our financial guidance. These statements are based on management's current expectations and information currently available, including current economic and industry conditions. These statements are not guarantees of future performance or actual results, and actual results, developments and business decisions may differ from those stated in this press release. The forward-looking statements are subject to future events, risks, uncertainties and other factors that could cause actual results to differ materially from those projected in the statements, including, but not limited to, the ability to enter into new contracts, maintain client relationships, manage the opening of new offices and offering of new services, the integration of new business mergers and acquisitions, the impact of COVID-19 on our business, as well as other economic and global market conditions and other risks and uncertainties detailed from time to time in SEC reports filed by ICON, all of which are difficult to predict and some of which are beyond our control. For these reasons, you should not place undue reliance on these forward-looking statements when making investment decisions. The word "expected" and variations of such words and similar expressions are intended to identify forward-looking statements. Forward-looking statements are only as of the date they are made and we do not undertake any obligation to update publicly any forward-looking statement, either as a result of new information, future events or otherwise. More information about the risks and uncertainties relating to these forward-looking statements may be found in SEC reports filed by ICON, including its Form 20-F, F-1, F-4, S-8, F-3 and certain other reports, which are available on the SEC's website at <http://www.sec.gov>.

### About ICON plc

ICON plc is a world-leading healthcare intelligence and clinical research organisation. From molecule to medicine, we advance clinical research providing outsourced services to pharmaceutical, biotechnology, medical device and government and public health organisations. We develop new innovations, drive emerging therapies forward and improve patient lives. With headquarters in Dublin, Ireland, ICON employed approximately 41,150 employees in 109 locations in 53 countries as at March 31, 2023. For further information about ICON, visit: [www.iconplc.com](http://www.iconplc.com).

ICON/ICLR-G

View source version on [businesswire.com](https://www.businesswire.com/news/home/20230626238713/en/): <https://www.businesswire.com/news/home/20230626238713/en/>

### Media contacts:

Claire Quinn  
Corporate Communications, ICON  
+353 87 4066091

[claire.quinn@iconplc.com](mailto:claire.quinn@iconplc.com)

Weber Shandwick (PR adviser)

Lisa Henry

+44 7785 458203

[lhenry@webershandwick.com](mailto:lhenry@webershandwick.com)

Source: ICON plc